At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 458 enrolled
Drug / intervention
P-3074 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness
In Brief
A Phase 3 clinical trial evaluating P-3074, Finasteride, and 2 other interventions for Alopecia, Androgenetic. Completed, enrolled 458 participants across 46 sites in 5 countries.
Detailed Summary
The purpose of this study is to confirm the clinical efficacy and the safety of P-3074 in participants with androgenetic alopecia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia, Androgenetic
CountriesBelgium, Germany, Hungary, Russia, Spain
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedDec 2016
Primary CompletionMar 2018
TodayJul 2026
First PostedDec 28, 2016
Enrollment StartAug 2, 2016
Primary CompletionMar 5, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.5 years ago
Interventions
P-3074drug
Finasteridedrug
P-3074 Vehicledrug
Finasteride Placebodrug